Details for Patent: 9,517,226

Which drugs does patent 9,517,226 protect, and when does it expire?

Patent 9,517,226 protects ENTRESTO and is included in one NDA.

This patent has thirty-eight patent family members in twenty-six countries.

Summary for Patent: 9,517,226

Title:	Inhibitors for treating diseases characterized by atrial enlargement or remodeling
Abstract:	The present invention relates to the NEP inhibitor pro-drug N-(3-carboxy-1-oxopropyl)-(4S)-p -phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the NEP inhibitor N-(3-carboxy-1-oxopropyl)-(4S)-p -phenylphenylmethyl)-4-amino-(2R)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. a human subject, in need of such treatment. The present invention further relates to a pharmaceutical composition or a commercial package comprising the NEP inhibitor or the NEP inhibitor pro-drug, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling.
Inventor(s):	Schumacher; Christoph (Bettingen, CH), Holbro; Thomas (Basel, CH)
Assignee:	Novartis AG (Basel, CH)
Application Number:	14/422,855
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,517,226

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620-001	Jul 7, 2015	AB	RX	Yes	No						TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620-002	Jul 7, 2015	AB	RX	Yes	No						TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION
Novartis Pharms Corp	ENTRESTO	sacubitril; valsartan	TABLET;ORAL	207620-003	Jul 7, 2015	AB	RX	Yes	Yes						TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION

Foreign Priority and PCT Information for Patent: 9,517,226

PCT Information
PCT Filed	August 22, 2013	PCT Application Number:	PCT/EP2013/067472
PCT Publication Date:	February 27, 2014	PCT Publication Number:	WO2014/029848

International Family Members for US Patent 9,517,226

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013304949
Brazil	112015003067
Canada	2882771